Skip to content
Search

Latest Stories

Pharmacy contractors can start claiming extra Covid-19 costs

The community pharmacy contractors now can start claiming their extra costs incurred due to the Covid-19 pandemic, as per an update posted by Pharmaceutical Services Negotiating Committee (PSNC).

The six-week period for claiming the costs began from Monday (July 5).


The move is a part of a deal reached between the PSNC and the government in June-end.

Last week, PSNC chief executive Simon Dukes also asked community pharmacy contractors in England to claim a range of costs incurred during the coronavirus pandemic.

As per the deal, contractors can get reimbursement for specific categories of Covid related costs incurred during March 1, 2020 and March 31, 2021 for the delivery of NHS pharmaceutical services.

All claims must be submitted between July 5 and August 15 using an agreed claim form provided by the NHS Business Services Authority (NHSBSA). The payments will be made on October 1.

While submitting claims, contractors need to set out their costs according to the categories suggested by the Department of Health and Social Care (DHSC), and indicate evidence for the same.

The categories include additional staff costs due to Covid-19, IT and communication costs to support remote working and virtual patient contact, expenditure on notified closures for infection control purposes and making the premises secure.

Contractors are advised to think carefully when making their claims as DHSC has not set out detailed evidence requirements, but may ask for it on a later stage.

Besides, owner of more than one pharmacy can submit one claim for all the premises.

To help contractors in making their claims, PSNC will issue a series of guidelines. The first of these was published on Monday (Jul 5).

More For You

After US and EU, UK approves Bavarian Nordic’s chikungunya vaccine

Bavarian Nordic plans to launch the vaccine in the UK in summer 2025

Getty Images

Chikungunya vaccine Vimkunya approved for use in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Vimkunya, a vaccine developed by Bavarian Nordic A/S to prevent chikungunya disease in people aged 12 years and older.

The UK approval follows earlier approvals by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025, making this the third regulatory green light for the vaccine.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less
Many patients report inaccuracies or missing details in their NHS medical records

Inaccurate information can result in serious harm or even death, warns Healthwatch England.

Image Credit: Getty Images

1 in 4 adults have spotted errors in their NHS medical records, survey finds

Healthwatch England has raised the alarm over the risks posed by inaccurate medical records as research reveals widespread errors in NHS patient information.

Commissioned by Healthwatch England and conducted by BMG Research, the survey polled a representative sample of 1,800 adults in England between 24 and 27 March 2025.

Keep ReadingShow less
Pharmacies NHS weight loss jabs

Pharmacies already sell the medication as a private service

Pic credit: iStock

Pharmacies in line to roll out NHS weight loss jabs

Pharmacies are “best placed” to deliver a planned rollout off greater access to weight loss jabs which could benefit 3.4 million people in England.

Reports today claim the government is looking at trials that would see the medication made available following a short, over-the-counter consultation for the price of an NHS prescription.

Keep ReadingShow less
Numark welcomes hub and spoke change, but calls for clear economic model

The H Human Medicines Regulations amendments will come into force on 1 October 2025.

Image credit: Getty Images

Hub and spoke dispensing between separate pharmacy businesses to begin in October

Community Pharmacy England (CPE) has confirmed that the government has laid amendments to the Human Medicines Regulations 2012 (HMR) in Parliament, marking a crucial step towards enabling hub and spoke dispensing between separate community pharmacy businesses.

The Human Medicines (Amendments Relating to Hub and Spoke Dispensing etc.) Regulations 2025 are set to come into force on 1 October 2025.

Keep ReadingShow less